Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

Published Results Also Show Potentially Differentiating Pharmacokinetic

Profile of Prodrug Stimulant

PHILADELPHIA, Nov. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced that Biological Psychiatry published the results of a study showing VYVANSE(TM) (lisdexamfetamine dimesylate), the first prodrug stimulant for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), provided significant efficacy in children for up to 12 hours. The published study also found that VYVANSE demonstrated low interpatient variability of measured pharmacokinetic parameters, as reported by the coefficient of variance (%CV).

This phase II randomized, double-blind, placebo- and active-controlled crossover analog classroom study in children aged 6 to 12 examined the efficacy and safety of VYVANSE (30 mg, 50 mg or 70 mg) and Adderall XR (mixed amphetamine salts extended-release: 10 mg, 20 mg or 30 mg) compared with placebo.

"This newly published research shows that VYVANSE provided a consistent time to maximum plasma concentration from patient to patient," said Ann S. Childress, M.D., President of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas, Nev. "This prodrug stimulant also demonstrated significant efficacy up to 12 hours after administration, which is something that my patients' parents are interested in as it may help to improve their family and homework time in the evening."

VYVANSE is a therapeutically inactive prodrug in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. Release of the active ingredient in VYVANSE does not rely on gastrointestinal factors such as gastrointestinal transit time and gastric pH.

Study Results Showed that VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- Fortune Oil and Gas, Inc. (OTCPink:FOGC), today announced that ... Inc. with the symbol (OTCPink : FOGCD). FINRA approved ... Also taking effect today is a ten for 1 ... event in the company,s progress according to CEO, ... proceed with the plan and still have any level ...
(Date:9/17/2014)... , Sept. 17, 2014  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that agreement has been reached ... on the design of a pivotal, Phase 3 ... for the treatment of cutaneous T-cell lymphoma (CTCL).  ...
(Date:9/16/2014)... , 17 settembre 2014 Hologic, Inc. ... il lancio in Europa del Tomcat, un nuovo ... una piattaforma multifunzionale completamente automatizzata, progettata per semplificare ... ed i rischi di errore legati alla gestione ... strumento Tomcat di Hologic riduce il carico di ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 3
... Reportlinker.com announces that a new market research report is ... http://www.reportlinker.com/p0484924/Epidemiology-Lupus.html In ... cases of systemic lupus erythematosus (SLE) in the seven ... women between 45 and 64 years of age. The ...
... NEW YORK, April 26, 2011 Reportlinker.com announces that ... catalogue: Epidemiology: Prostate Cancer ... period, prostate cancer incident cases will increase in all ... likely to be as a result of an aging ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Lupus 2Reportlinker Adds Epidemiology: Prostate Cancer 2
(Date:9/17/2014)... 17, 2014 The global metrology services ... due to the key driving factors of increasing demands ... CAGR of 8.2 % puts the metrology services market ... 2018, as stated in a Transparency Market Research report ... Share, Growth, Trends, and Forecast 2012 – 2018”. , ...
(Date:9/17/2014)... This news release is available in Spanish . ... overweight affect more than half of the population in ... organism, one of which affects liver function. Fat accumulates ... circumstances, causes inflammation, fibrosis and finally, cirrhosis. To date, ... been hepatic biopsy. Imaging techniques such as abdominal ecography ...
(Date:9/17/2014)... (GSA) invites all journalists to attend its ... interdisciplinary conference in the field of aging from ... may register free of charge. , An estimated 4,000 ... the Walter E. Washington Convention Center and Marriott Marquis ... From Cells to Societies" and the program schedule contains ...
(Date:9/17/2014)... September 17, 2014 Representatives with Capitol ... sponsor of Thursday’s Anti-Defamation League Event at the Four Seasons ... we consider it an honor to be a sponsor for ... Pain Institute. , Schocket went on to explain that the ... 600 community leaders and members at the Four Seasons to ...
(Date:9/17/2014)... Neon Sport and Fitmark have an ... industry’s most anticipated event, Joe Weider's Olympia Fitness & ... each take home a Neon Sport branded Fitmark Power ... gear. Fitmark will hold entries for the special prize ... , “There’s nothing more exciting than seeing our ...
Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2
... anti-HLA antibody assays both contribute to characterization ... ... immunosuppression, COLUMBIA, Md., June 1 Data developed by Cylex ... the American Transplantation Congress in Toronto, Canada, suggest,that cell-mediated immunity and ...
... also helped with severe fatigue among patients on chemotherapy ... the more common and unpleasant side effects of treatment ... by the ancient Chinese practice of acupuncture. , A ... and pain and shoulder dysfunction after neck dissection in ...
... treatment of choice for advanced, metastatic prostate cancer has ... testosterone the hormone that fuels prostate-cancer growth ... drugs. While such therapy buys time for patients, it ... resistant to the androgen deprivation and continues to grow. ...
... VA Three new studies published in the June ... focus on what role gender plays in the prognosis ... and the success rates of hearing aid implants in ... the wide variety of critical research being undertaken every ...
... pancreatic, kidney cancers, respectively , , SATURDAY, May ... cancer -- which historically carries a grim prognosis ... cancer drug Gemzar was used after surgery, new ... of pancreatic cancer patients are even candidates for ...
... death for female survivors; cardiovascular events for males ... survived Hodgkin lymphoma as children have an increased risk ... disease as adults, according to a new report. ... -- may help drive these increased risks, according to ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health 2Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Hodgkin Lymphoma Kids Face Greater Risk of Future Problems 2
... WardWatch has been designed specifically ... medical staff involved in ward rounds. ... medications and dosages, and consultations that ... (Specialist) or Registrar during Ward round ...
... is an advanced medical calculator ... Pediatric Dosing and Critical Care ... a logical complement to other ... the Daviss Drug Guide, PDR ...
... comprehensive guide provides safe, effective, ... information in a quickly accessible ... edition includes the latest drugs ... key nursing implications are highlighted ...
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
Medicine Products: